Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
BioNTech SE is a German biotechnology company headquartered in Mainz, Germany. Alongside Pfizer, it developed a COVID-19 vaccine now approved by the U.S. Food and Drug Administration for emergency use. Investors can back the company by purchasing American Depositary Receipts (ADRs) on the Nasdaq under the ticker symbol BNTX.
On Nov. 9, Pfizer released a statement based on an early analysis of the two-dose COVID-19 vaccine it’s developing with BioNTech. The company says its vaccine is 95% effective in preventing COVID-19 in patients with no evidence of prior infection.
That said, the protection rate of the vaccine could change by the time its study ends. This is encouraging data — but it’s early data. And it hasn’t been peer-reviewed.
On December 2, the UK became the first country to officially approve the Pfizer-BioNTech COVID-19 vaccine for emergency use. The first round of vaccines is expected to roll out in the following weeks to front-line medical workers and residents of long-term care homes.
Pfizer is also preparing an application to the U.S. Food and Drug Administration (FDA) for emergency-use approval. Canadian Prime Minister Justin Trudeau has placed an order for 20 million doses of the vaccine, stating the vaccine will be deployed as soon as it’s approved by Health Canada.
In response to Pfizer’s announcement, the S&P 500 rose 2.8%, the Dow Jones Industrial Average surged by 1,092 points, Pfizer’s stock saw a 9% increase and BioNTech’s stock saw a 14% increase.
Pfizer expects to produce over 50 million doses in 2020 and up to 1.3 billion doses in 2021. A panel advising the Centers for Disease Control recommended December 1 that the first doses go to health-care workers and the staffs of nursing homes and care facilities.
Since the stock market crash in March caused by coronavirus, BioNTech's share price has had significant positive movement.
Its last close price was $348.68, which is 90.72% up on its pre-crash value of $32.35 and 1,145.29% up on the lowest point reached during the March crash when the shares fell as low as $28.00.
If you had bought $1,000 worth of BioNTech shares at the start of February 2020, those shares would have been worth $1.00 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $11.00.
|52-week range||$58.81 - $464.00|
|50-day moving average||$359.06|
|200-day moving average||$223.95|
|Wall St. target price||$334.31|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$18.24|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-10)||-0.15%|
|1 month (2021-08-18)||-4.21%|
|3 months (2021-06-18)||64.15%|
|6 months (2021-03-18)||236.40%|
|1 year (2020-09-17)||422.13%|
|2 years (2019-09-14)||N/A|
|3 years (2018-09-14)||N/A|
|5 years (2016-09-14)||N/A|
Valuing BioNTech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioNTech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioNTech's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, BioNTech shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
BioNTech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.0724. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioNTech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
BioNTech's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $5.6 billion.
The EBITDA is a measure of a BioNTech's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$7.8 billion|
|Operating margin TTM||71.2%|
|Gross profit TTM||$-222,037,000|
|Return on assets TTM||68.31%|
|Return on equity TTM||133.85%|
|Market capitalisation||$87.1 billion|
TTM: trailing 12 months
There are currently 2.1 million BioNTech shares held short by investors – that's known as BioNTech's "short interest". This figure is 2.4% up from 2.1 million last month.
There are a few different ways that this level of interest in shorting BioNTech shares can be evaluated.
BioNTech's "short interest ratio" (SIR) is the quantity of BioNTech shares currently shorted divided by the average quantity of BioNTech shares traded daily (recently around 6.2 million). BioNTech's SIR currently stands at 0.34. In other words for every 100,000 BioNTech shares traded daily on the market, roughly 340 shares are currently held short.
However BioNTech's short interest can also be evaluated against the total number of BioNTech shares, or, against the total number of tradable BioNTech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioNTech's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 BioNTech shares in existence, roughly 10 shares are currently held short) or 0.0273% of the tradable shares (for every 100,000 tradable BioNTech shares, roughly 27 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioNTech.
Find out more about how you can short BioNTech stock.
We're not expecting BioNTech to pay a dividend over the next 12 months.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc. ; Sanofi S.
Everything we know about the MiNK Therapeutics IPO, plus information on how to buy in.
Everything we know about the Wetouch Technology IPO, plus information on how to buy in.
Everything we know about the Life Time Group Holdings IPO, plus information on how to buy in.
Everything we know about the Slinger Bag IPO, plus information on how to buy in.
Everything we know about the NSTS Bancorp IPO, plus information on how to buy in.
Everything we know about the Volcon IPO, plus information on how to buy in.
Everything we know about the Thomas James Homes IPO, plus information on how to buy in.
Everything we know about the FGI Industries IPO, plus information on how to buy in.
Everything we know about the Zhong Yang Financial Group IPO, plus information on how to buy in.
Everything we know about the Exscientia Ltd IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.